To further validate these findings, we analyzed an independent published scRNA-seq dataset from breast cancer patients treated with a PD-L1 inhibitor plus chemotherapy (GSE266919).28 Notably, despite differences in therapeutic regimens (NK cell therapy vs. PD-L1 inhibitor) and tumor types (pancreatic cancer vs. breast cancer), we still observed that c4-ZEB2 and c10-NCR3 exhibited greater expansion patterns in responders than in nonresponders (Supplementary Fig. 6a, b), which was consistent with the trends in our dataset. This evidence concerns the gene CD274 and breast cancer.